吉隆坡, 2025年12月16日 - (亚太商讯 via SeaPRwire.com) - CBL International Limited（纳斯达克股票代码：BANL）（"公司"或"CBL"），万利集团（"万利"或"集团"）的上市主体，欣然宣布公司荣获享有盛誉的EcoVadis银奖，跻身全球可持续发展表现评估前15%的企业行列。EcoVadis银奖认可CBL在四个关键维度上建立的稳健可持续发展管理体系和全面的企业责任方法：环境、劳工与人权、道德规范以及可持续采购。这一成就体现了公司将可持续发展融入核心业务运营和价值链的坚定承诺。万利集团集团主席兼行政总裁谢威廉博士表示："荣获EcoVadis银奖是一个重要的里程碑，验证了我们对负责任商业实践的持续投入。在CBL，可持续发展不是附加项，而是我们日常运营的核心。这一认可反映了我们团队共同努力打造一个既能实现商业成功又能产生积极社会影响的企业。"EcoVadis评估基于联合国全球契约、ISO 26000和国际劳工组织公约等国际标准，分析企业可持续发展管理体系，将CBL置于全球85%以上的领先位置。要获得银奖资格，CBL需在所有可持续发展主题上展现强劲表现，并在每个类别中达到严格的最低得分要求。这一成就正值CBL持续推进其可持续发展倡议之际，包括通过生物燃料分销和新一代燃料开发致力于海事脱碳。公司最近报告2025年上半年生物燃料销售额同比增长154.7%，展示了环境管理与业务增长如何相辅相成。CBL的可持续发展之旅包括可衡量的碳减排目标、道德供应链治理、社区投资项目以及透明的ESG报告。公司近期英国皇家特许管理会计师公会 2025年度大奖中荣获"卓越可持续发展奖"，以及谢威廉博士获得由香港董事学会（HKIoD）颁发的"年度董事大奖—上市企业执行董事类别"，进一步彰显了其在可持续海事物流领域的领导地位。公司将继续致力于提升可持续发展绩效，计划进一步加强环境倡议、增强社会影响项目，并深化与全球最佳实践一致的治理框架。 照片说明：CBL INTERNATIONAL LTD 荣获EcoVadis银奖，该奖项授予在奖牌颁发日期前 12 个月内由 EcoVadis 評估其可持續發展表現的全球前 15% 的公司。关于万利集团 万利集团成立于 2015 年，以CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖65个港口。集团积极推动可持续燃料，并已取得ISCC EU和ISCC Plus认证。 如欲了解更多信息，请到集团网站 https://www.banle-intl.com 浏览。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, December 15, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX: 1952.HK) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session and briefly reached an intraday high of HKD 48.54. By market close, the stock was trading at HKD 46.88, with the share price remaining at relatively elevated levels throughout the session, representing a gain of 4.55%, indicating a positive market response.According to market commentary, the strong performance on the day reflected both investor focus on the Company’s newly articulated medium- to long-term strategy and confidence signals released earlier by Directors and substantial shareholder. Previously, the Company also announced that certain Directors and a substantial shareholder have increased their shareholdings in the Company. On December 12, 2025, Mr. Wei Fu, Non-executive Director, Honorary Chairman of the Board and a substantial shareholder of the Company; Mr. Yifang Wu, Executive Director and Chairman of the Board; Mr. Rogers Yongqing Luo, Executive Director and Chief Executive Officer; and Mr. Ian Ying Woo, Executive Director, President and Chief Financial Officer, collectively acquired 846,659 ordinary shares of the Company through open-market transactions, for a total consideration exceeding HK$38 million, representing an average price of approximately HK$45.01 per Share. In addition, the Company has been informed that CBC Group, a substantial shareholder of the Company, has further undertaken that it plans to increase its shareholding by not more than 1% in aggregate in the following three to six months, subject to the market conditions and compliance with applicable laws and regulatory requirements. The relevant actions are seen as a clear indication of Directors and substantial shareholders' positive stance on the company's long-term development prospects.The Company's 2030 strategy sets out a dual-engine approach to deliver predictable near-term growth and value creation through commercialization of existing assets, business development partnerships, and in-house R&D milestones, while driving long-term growth and value creation through in-house R&D and discovery, as well as global commercial expansion. Everest Medicines will continue to strengthen its leadership in core therapeutic areas, advance the development and commercialization of innovative therapies, and build a globally competitive biopharmaceutical company with sustainable growth.Everest Medicines focuses on renal, autoimmune, critical care, cardiovascular, and ophthalmic disease area, advancing its pipeline through a combination of in-licensed innovative assets and in-house R&D. By 2030, the Company aims to build a high-value commercial product portfolio while selectively expanding into additional valuable therapeutic areas with blockbuster potential.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle. By 2030, Everest Medicines targets annual revenue exceeding RMB 15 billion, including approximately RMB 9 billion from its existing pipeline and RMB 6 billion from newly in-licensed assets, while also exploring potential out-licensing opportunities. Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafter. Over the same period, the number of commercial products is expected to exceed 20, including NEFECON®, Velsipity®, XERAVA®, cefepime–taniborbactam, and Lerodalcibep.To support its international growth, Everest Medicines is advancing a global strategy focused on strengthening regulatory and clinical development capabilities, while progressively building commercial infrastructure across Europe, the United States, and emerging markets. By 2030, the Company aims to drive growth through a combination of overseas out-licensing and direct commercialization, accelerating its global expansion.Notably, as a major shareholder of NovaBridge Biosciences, holding approximately 16% of its issued share capital, the Company will collaborate with NovaBridge Biosciences to identify high-quality assets and enhance global R&D and commercialization capabilities through complementary strengths and resources."The 2030 Strategy reflects Everest Medicines' clear vision for commercialization, R&D, and global expansion, and reinforces the Company's ability to deliver sustainable value. Since its founding in 2017, the Company has built a strong foundation through in-licensing innovative assets, completing its IPO, and executing a dual-engine strategy focused on high-potential therapeutic areas and strong commercialization and R&D capabilities," said Mr. Wei Fu, Honorary Chairman of the Board of Everest Medicines and CEO of CBC Group. "CBC Group will continue to leverage its global resources and ecosystem to support the Company's growth, spanning pipeline advancement, platform building, and organizational expansion. The recent share purchases by the Directors and CBC Group's announced intention to increase its shareholding further demonstrate strong confidence in Everest Medicines' long-term prospects.""The 2030 Strategy marks a key milestone for Everest Medicines, guiding growth through BD partnerships and in-house R&D to build a larger commercial portfolio and pursue new high-potential blockbuster opportunities. Leveraging its BD capabilities and the CBC ecosystem, the Company plans to add three-to-five late-stage, high-value assets annually, aiming for peak sales within three years of reimbursement, with more than 20 new assets expected to contribute around RMB 6 billion by 2030 and RMB 30 billion by 2035. Our strong balance sheet and cash flow from commercial activities will support the implementation of our strategic initiatives." said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "We will also continue to advance our in-house R&D platforms and, through our collaboration with Hasten, strengthen the late-stage pipeline and market reach.""Everest has established a scalable commercialization platform integrating medical, access, marketing, and sales capabilities," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "As a chronic disease therapy, NEFECON® generated over RMB 1 billion in sales during the first three quarters of its first full year following commercial launch, validating our commercial effectiveness. Building on this success, we will extend our commercial model and expertise from renal and anti-infective therapies to additional therapeutic areas, while advancing our in vivo mRNA CAR-T and mRNA tumor vaccine platforms, addressing unmet medical needs in China and globally."Overall, the release of Everest Medicines' 2030 strategy not only sets out a systematic roadmap for future business development but also, through proactive share purchases by Directors and substantial shareholder, reflects aligned internal and external confidence in the Company's long-term prospects. Looking ahead, guided by its dual-engine strategy, Everest Medicines aims to strengthen its position in core therapeutic areas and innovative drug R&D, while building a globally competitive biopharmaceutical company with sustainable growth. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2025年12月16日 - (亚太商讯 via SeaPRwire.com) - 全球创新药估值修复与18A赛道稀缺标的争夺白热化的背景下，青岛国资深度背书的华芢生物-B（02396.HK）正式启动港股招股，以"港股PDGF第一股"的独特定位，成为年末国际配售市场的核心聚焦点。公司拟全球发售1764.88万股股份，其中国际配售占比90%（1588.38万股），香港公开发售占比10%（176.50万股），招股期至12月17日，最高发售价51.00港元，预计12月22日于港股主板挂牌。在同期六支新股并行、资金面分散的市场环境下，华芢生物凭借糖足管线的全球稀缺性、难以复制的技术壁垒、清晰的商业化路径及充足的现金流储备，精准契合全球长线机构对"确定性成长+高壁垒资产"的配置逻辑，而其核心糖足管线Pro-101-2一旦实现商业化，将成为全球范围内屈指可数的PDGF稀缺资产，开启千亿级创面愈合市场的价值重估。糖足特效药的"全球存在"与"中国缺席"：不是无药，是"用不上"糖尿病足作为糖尿病最致命的慢性并发症，正以庞大的患者基数与严峻的治疗现状，催生千亿级刚性医疗需求。根据世界卫生组织定义，糖尿病足是由神经病变和血管缺血引发的足部溃疡、感染甚至组织坏死，严重时需截肢保命，其治疗复杂且昂贵。据招股书披露，我国糖尿病患者已达1.4亿，其中糖足患病人数已突破840万，随着老龄化加速与糖尿病年轻化趋势加剧，这一数字仍在持续攀升。更令人揪心的是，糖足的致死致残率居高不下，尤其是截肢患者年死亡率更是达到22%，远超部分癌症，而传统疗法的局限性让这一困境雪上加霜。当前临床治疗仍停留在"清创+抗生素+基础护理"的传统模式，无法解决血管神经病变导致的慢性创面修复障碍，愈合率长期低于50%，给医保基金带来沉重负担。更严峻的是，全球范围内PDGF药物领域已沉寂27年——自1997年首款PDGF药物Regranex获FDA批准后，全球再无第二款同类产品上市，其15g规格售价高达1700美元，且未进入中国市场，国内患者难以企及。而国内市场长期处于国产PDGF药物"零获批"状态，临床需求与供给空白形成鲜明对比。而华芢生物核心糖足管线Pro-101-2作为已进入II期临床阶段的PDGF药物，其"血管新生-组织修复"双效机制可从根源上解决慢性创面愈合难题，每年为医保基金节约超亿元支出，完美契合医保提质控费的核心诉求，具备强大的市场渗透潜力。弗若斯特沙利文数据显示，2033年国内仅糖足市场规模将达485亿元，而整个伤口愈合市场将突破1180亿元，这片千亿蓝海正等待真正的破局者出现。技术护城河：13年积淀铸就全球稀缺竞争力PDGF药物并非普通企业可轻易涉足的领域，其背后是长达数十年的研发积淀、工艺突破与人才积累，从量变到质变的壁垒让竞争对手望尘莫及，而华芢生物历经13年深耕，已构建起"技术+工艺+专利"的三重护城河，成为全球PDGF领域的稀缺玩家。PDGF作为血小板损伤后分泌的强效生长因子，通过激活细胞信号通路促进成纤维细胞增殖与肉芽生长，是慢性创面愈合的"黄金钥匙"，但其分子结构复杂、稳定性差、生产工艺严苛，成为全球药企的研发禁区。华芢生物通过基因序列优化，剔除了5个易裂解氨基酸，显著提升了药物在人体内的稳定性与活性；生产端，公司采用毕赤酵母表达系统，相较于酿酒酵母，活性提升75倍，不仅解决了产能受限问题，更实现单位生产成本的大幅下探，打破了海外竞品的天价垄断，让国内患者"用得上、用得起"保肢药物。临床数据充分验证了技术突破的价值。Pro-101-2的I期临床结果显示其安全耐受性优良，无严重不良事件及死亡病例报告，而其针对中重度糖足的治疗优势尤为突出——可覆盖Wagner1-3级患者，既能促进慢性创面愈合，更能阻止轻症向重症恶化，填补了国内中重度糖足治疗的空白。该管线有望于2030年实现上市，成为国内首款糖足治疗PDGF药物。专利布局方面，公司已构建54项已授权及待批专利矩阵，从分子序列、表达系统到制剂工艺、适应症拓展形成全链条保护，为竞争对手设置了难以突破的知识产权屏障。这种"技术+工艺+专利"的三重壁垒，让PDGF赛道形成近乎独家的竞争格局，而华芢生物作为唯一持续推进的企业，其稀缺性在全球创新药领域尤为珍贵。商业化确定性：资金-研发-商业化正向闭环，铸就机构青睐的18A稀缺标的对国际配售机构而言，清晰的商业化路径与充足的资金储备是规避研发型企业风险的核心，而华芢生物凭借"糖足+烧烫伤"双管线协同以及多重风险对冲优势，成为"风险可量化、成长可预期"的稀缺配置标的。多重风险对冲优势进一步强化了机构配置信心。青岛国资作为核心股东，不仅为公司提供资金支持，更使其成为地方政府重点扶持的生物医药名片，在研发资源对接、政策协同、产业化等方面具备显著优势。其联席保荐人中信证券2025年在18A赛道表现亮眼，保荐的7个项目均实现首日未破发，其中映恩生物、劲方医药等首日涨幅超100%，12月10日挂牌的宝济药业更是录得3526.34倍公开发售认购、暗盘一度暴涨超115%的佳绩，亦强化市场信心。更值得关注的是，公司已完成2000L规模商业化生产工艺，具备从临床到商业化的完整技术衔接能力，且PDGF药物通过缩短住院时间、降低截肢率，与DRG/DIP支付改革方向高度契合，商业化路径明确。此外，公司具备"小流通盘+纯正18A属性"优势，未来有望快速进入港股通，参考历史数据，港股通纳入后南向资金的持续配置将为股价提供显著流动性溢价，契合机构对资产流动性的核心要求。在全球创新药估值修复、18A赛道稀缺标的争夺加剧的背景下，华芢生物正站在"国产PDGF第一股"的关键节点。其核心糖足管线Pro-101-2一旦实现商业化，将成为全球范围内屈指可数的PDGF稀缺资产，打破27年的技术垄断与市场空白，切入千亿级刚需市场；而烧烫伤管线的率先落地将奠定现金流基础，打开长期成长空间。对国际配售机构而言，这家兼具"国资护航+技术壁垒+刚需属性+优质保荐+现金流闭环"的18A稀缺标的，不仅具备清晰的临床推进路径与商业化前景，更有望凭借港股通预期与赛道稀缺性实现价值重估。华芢生物正迎来临床价值与资本市场价值的双重兑现期，为全球长线机构提供了年末布局"确定性成长+高壁垒资产"的优选机遇，而其作为全球PDGF领域稀缺玩家的价值，也将在商业化进程中持续凸显。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2025年12月16日 - (亚太商讯 via SeaPRwire.com) - 12月15日，康哲药业控股有限公司（"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）拥有相关许可权利的创新口服JAK1抑制剂povorcitinib（拟定中文通用名：磷酸泊沃昔替尼片）（"povorcitinib"或"产品"）已获中国国家药品监督管理局（"NMPA"）药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。此次认定有望加快该产品的研发与审评进程。Povorcitinib是一种选择性口服小分子JAK1抑制剂，在区域内特定国家/地区拥有物质和用途专利。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎（HS）和结节性痒疹的3期临床试验。另外，治疗哮喘的2期临床试验也在进行中。2023年3月，Incyte公布povorcitinib达到了非节段型白癜风的全球多中心2b期临床研究的主要终点。结果显示：治疗24周，与安慰剂相比，接受每日一次povorcitinib治疗的患者的全身皮损显著复色。随后该2b期试验的扩展期结果表明，长期使用povorcitinib可进一步促进全身和面部的复色，且耐受性良好[1]。2025年8月，德镁医药获NMPA签发的药物临床试验批准通知书，同意开展povorcitinib用于治疗非节段型白癜风等适应症的临床试验。德镁医药已启动产品在中国的临床开发工作，并考虑择机在中国推动其治疗HS和结节性痒疹等皮肤相关疾病的临床开发。白癜风是一种慢性自身免疫性疾病，其特征是皮肤色素脱失，其发病原因为产生色素的细胞即黑素细胞的缺失。据估算，中国约有1030万人患有白癜风，其中约820万人患有非节段型白癜风[2]。目前白癜风疗法选择有限且难以治疗，特别是对于累及面积大的白癜风患者。若于中国获批，povorcitinib有望为非节段型白癜风患者提供差异化的治疗选择。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。若于中国获批上市，该产品将有望与德镁医药在售创新药益路取（替瑞奇珠单抗注射液）、在售独家药喜辽妥（多磺酸粘多糖乳膏）及正处于新药上市申请（NDA）阶段的创新药磷酸芦可替尼乳膏形成协同，推动产品快速实现临床和商业价值，惠及更多皮肤疾病患者。此外，该产品还将与外用磷酸芦可替尼乳膏共同为白癜风患者提供差异化、全面的治疗选择。康哲药业于2024年3月31日，通过德镁医药的附属公司与Incyte就povorcitinib订立合作和许可协议（"许可协议"），获得在中国大陆、香港特别行政区、澳门特别行政区、台湾地区及东南亚十一国（"区域"）研究、开发、注册及商业化产品的独家许可权利，以及在区域内生产产品的非独家许可权利。德镁医药的附属公司已将povorcitinib除中国大陆外的其他区域的相关权利再许可予康哲药业（不包括德镁医药及其附属公司）。关于康哲药业康哲药业是一家链接医药创新与商业化，把控产品全生命周期管理的开放式平台型企业，致力于提供有竞争力的产品和服务，满足尚未满足的医疗需求。康哲药业专注于全球首创（FIC）及同类最优（BIC）的创新产品，并高效推进创新产品临床研究开发和商业化进程，赋能科研成果向诊疗实践的持续转化，造福患者。康哲药业聚焦专科领域，拥有被验证的商业化能力，广泛的渠道覆盖和多疾病领域专家资源，核心在售产品已获领先的学术与市场地位。康哲药业围绕优势专科领域不断纵深发展，以巩固心脑血管/消化/眼科/皮肤健康业务竞争力，带来专科规模效率，其中皮肤健康业务（德镁医药）已成为其细分领域的龙头企业，并拟于联交所独立上市。同时，康哲药业持续推动研产销全产业链在东南亚及中东区域运营发展，以获取新兴市场的增量，助力集团实现高质量可持续发展。参考文献/资料1. 产品非节段型白癜风适应症的全球多中心2b期临床结果可在Incyte官网查询：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. 数据来自灼识咨询报告康哲药业免责与前瞻性声明本新闻无意向您做任何产品的推广，非广告用途。本新闻不对任何药品和医疗器械和/或适应症作推荐。若您想了解具体疾病诊疗信息，请遵从医生或其他医疗卫生专业人士的意见或指导。医疗卫生专业人士作出的任何与治疗有关的决定应根据患者的具体情况并遵照药品说明书。由康哲药业编制的此新闻不构成购买或认购任何证券的任何要约或邀请，不形成任何合约或任何其他约束性承诺的依据或加以依赖。本新闻由康哲药业根据其认为可靠之资料及数据编制，但康哲药业并无进行任何说明或保证、明述或暗示，或其他表述，对本新闻内容的真实性、准确性、完整性、公平性及合理性不应加以依赖。本新闻中讨论的若干事宜可能包含涉及康哲药业的市场机会及业务前景的陈述，该等陈述分别或统称为前瞻性声明。该等前瞻性声明并非对未来表现的保证，存在已知及未知的风险、不明朗性及难以预知的假设。康哲药业并不采纳本新闻包含的第三方所做的任何前瞻性声明及预测，康哲药业对该等第三方声明及预测不承担责任。 Copyright 2025 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - December 15, 2025) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to provide the latest progress update on the Graphene Aluminium-Ion Battery technology ("G+AI") being developed by GMG and the University of Queensland ("UQ") under a Joint Development Agreement with Rio Tinto, one of the world's largest metals and mining groups, and with the support of the Battery Innovation Center of Indiana ("BIC") in the United States of America.Based on its current state of development as reflected below, the GMG G+AI Battery has similar performance characteristics to those provided by High Power Lithium Titanate Oxide ("LTO") batteries, which are sold at a premium price of up to US$1500/kWh. However, the GMG G+AI Battery can be produced at a substantially lower cost and therefore can be priced below that of LTO batteries. In 2025, sales of LTO batteries, which are used in many applications globally, totalled US$ 5.6[1] billion.Battery Performance Update:GMG is pleased to announce that it has progressed its G+AI Battery technology and believes that, once development is completed, it can meet the key target specification requirements for the main targeted battery use case as per Figure 1, including:Charging in under 6 minutes;Energy density > 100 Wh/kg after 1 hour of charging;Long Cycle Life (10,000 cycles);Safe (no Lithium);Lower Thermal Runaway Risk; andLikely no thermal management system will be needed.Bob Galyen, GMG Non-Executive Director, commented: "In my nearly five decades in the battery industry, I have rarely seen a technology with the disruptive potential of GMG's next-generation graphene aluminium-ion battery. With the possibility of charging from empty to full in around six minutes, this chemistry fundamentally changes how designers can think about electric vehicles, consumer electronics, and stationary storage. Instead of planning around long charge stops with large packs, engineers can optimise for rapid energy turnaround, with higher power, and safer, with GMG's battery made from abundant raw materials. Lithium-ion will remain a key part of the energy landscape for years to come, but its limitations in fast charging, temperature tolerance, and critical-mineral supply are increasingly evident. By leveraging aluminium and graphene, the GMG team is demonstrating a pathway to reduce reliance on traditional lithium-based systems while delivering step-change improvements in charge time and power density. This is not an incremental tweak to existing cells - it is a new platform that can open markets and use cases that were previously uneconomic or impractical. As GMG moves from the lab toward scaled manufacturing, its primary focus is on proving reliability, safety, and cost at industrial level. Automotive, grid, and specialty-device partners are already engaging with GMG to explore pilot programs and early integrations. The companies that adapt quickest to this shift will lead the next wave of electrification, and GMG intends to be at the centre of that transition with graphene aluminium-ion technology."Figure 1: G+AI Battery Use Case - heavy mobile equipmentTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_gmg_figure1.jpgGMG is pleased to share the energy densities of the current GMG G+AI pouch cell at 60 minutes and 6-minute charging compared to other chemistry batteries on the market (Figure 2), and a voltage vs capacity graph (Figure 3) of its latest G+AI Battery technology based on data provided by the third-party BIC battery testing laboratory.Based on that testing, the current stage of development, batteries produced by GMG and BIC had an energy density of 58 Wh/kg when charged in 1 hour and 26 Wh/kg when charged in 6 minutes. In 6-minute fast charging, the battery cells achieved 62% capacity in 3.2 minutes. The batteries had a nominal voltage of approximately 3.0 Volts and maintained performance over hundreds of cycles at 6-minute fast charging, without the significant degradation typically observed in lithium and sodium-ion batteries at such high charging rates.Figure 2: Different Battery Chemistry Performance at 6 min and 60 min Charge[2]To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_002full.jpgStandard commercial Lithium Nickel Manganese Cobalt ("LNMC") and Lithium Iron Phosphate ("LFP") battery cells for electric vehicles and stationary storage are not designed for continuous 6-minute charging (10C); typical recommended charge rates are ≤1 hour (1C), often 2 hours (0.5C), with only limited fast charge operation. Only specialized high-power cell designs like LTO battery cells can tolerate charge rates of 6 minutes (10C).[3]Figure 3: Battery performance curves of GMG's G+AI Battery at 60 min and 6min chargeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_003full.jpgGMG has now developed a completely new hybrid electrolyte that is chloride free and noncorrosive, unlike common aluminium battery electrolytes, along with a complex cathode and anode technology that enables very stable fast charging over several cycles. The substrate for both the cathode and anode in the GMG G+AI Battery is aluminium foil - which provides significant cost and weight savings compared with copper, the substrate material used in most lithium and sodium-ion batteries. GMG's technology does not include the use of lithium or copper. The Company has submitted an additional patent application covering these new developments.Craig Nicol, GMG Managing Director and CEO, commented: "I couldn't be happier with the GMG team to get to this point with our battery. We have rebuilt this battery in our weekly sprints from the ground up and developed completely new complex cathode, anode and electrolyte. This will provide a next generation fast charging battery technology currently not available in the world, and we look forward to sending out sample cells to test with partners in early 2026. This technology has many years of development in front of it and will improve as we keep pushing through known issues to improve capacity, voltage and reduce weight."GMG management believes that the Company's battery technology can eventually achieve over 150 Wh/kg when charged in 1 hour, and over 75 Wh/kg when charged in 6 minutes. The Company believes further development of the cathode, anode, electrolyte and component weights will eventually achieve this end goal.Figure 4 shows the latest Graphene Aluminium-Ion Battery multi-layer pouch cell.Figure 4: Current Multi-Layer Battery Pouch CellTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_004full.jpgBattery Technology Readiness LevelThe battery technology readiness level ("BTRL") of the G+AI technology remains at Level 4, see Figure 5. GMG is currently optimizing electrochemical behaviour for pouch cells via ongoing laboratory experimentation. Through collaboration with BIC, it is anticipated that the battery technology readiness will progress to BTRL 7 and 8 since the equipment and processes needed to produce the G+AI batteries are the same as those employed to make Lithium-Ion Batteries.Figure 5: Battery Technology Readiness Level (BTRL)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_005full.jpgThe Company is confident it can meet the overall timeline, as seen in Figure 6, of its battery cell roadmap that calls for testing of cells with customers in 2026 and small commercial production with support of various partners, including BIC, in 2027.Figure 6: Battery Cell RoadmapTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_006full.jpgNext Steps Toward Commercialisation & Market ApplicationsJack Perkowski, GMG Chairman and Non-Executive Director, commented: "I am extremely proud that GMG has progressed its battery to this stage. It is a significant milestone for the Company because the battery technology has so much opportunity in so many applications - especially in commercial vehicles. I look forward to the next updates as GMG makes further progress in the development of its battery technology."The Company continues to see a broad range of applications for a completed GMG G+AI Battery - utilising its ultra-high power-density and economic energy density characteristics. Along with Rio Tinto, a range of global companies have confidentially expressed their interest in working with GMG in the following vertical sectors:Figure 7: Market ApplicationsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_007full.jpgCurrently, GMG believes it will use a plastic battery pack design, similar to Figure 8, to hold the battery pouch cells - reducing the weight, cost and complexity of using a metal case. Using a plastic battery pack is possible for two main reasons - GMG believes that its battery will not require a thermal management system or the fireproofing precautions provided by the metal case in a lithium-ion battery. Using plastic will increase the comparative energy density of GMG's G+AI battery packs when compared to lithium-ion batteries.Figure 8: Expected Battery Pack for G+AIB Pouch CellsTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/278044_3e8dbe4f44c75b4b_008full.jpgComparison and Market Review: LTO Batteries As shown in Figure 9 below, the performance of GMG's G+AI battery technology is already very similar to LTO batteries.Figure 9: Comparison of Graphene Aluminium-Ion Battery (G+AI) to Lithium Titanate Oxide (LTO) BatteryParameterHigh Power LTO[4]GMG G+AI BatteryRapid Charging80% in 6 minutes100% in 6 minutesEnergy Density - 6-minute charge37 Wh/kg (80% of Capacity)46 Wh/kg (6 min +)26 Wh/kg(Current)Large upside to be confirmedDepth of DischargeFull RangeFull RangeSafetySafeSafer (no lithium fire potential)Longevity70% performance over 20,000 cyclesTo be confirmedBattery PriceUS$800 - US$1500 / kWh[5]Lower price due to lower material costsNo lithium, no TitaniumMarket SizeUS$5.6 Billion in Sales in 2025Under development LTO batteries are sold at a premium to LFP and LNMC batteries, which are the main chemistries used in electric vehicles and energy storage systems, and are also widely used in other electronic applications due to their high performance and long cycle life. The material and manufacturing costs for GMG's G+AI Battery are expected to be similar to, or less than, the cost to manufacture standard lithium-ion batteries, but substantially lower than the costs to produce LTO batteries.LTO batteries have energy density ranging from 50 - 80 Wh/kg.[6] The LTO product is sold globally for use in many applications - with a total of US$5.6[7] billion sales per annum in 2025. Sales of LTO batteries are expected to grow at 10% per annum to an estimated US$ 9.0 billion by 2030. The major manufacturers of LTO batteries include Toshiba, Gree, Microvast and CATL.Further details on applications for the LTO battery from Mordor Intelligence7 are described below. In many of the use cases for LTO batteries, GMG believes that its G+AI Battery can be substituted at a substantially lower cost.Commercial Vehicles: Automotive, primarily buses, refuse trucks, and drayage tractors rather than passenger cars, is the largest user of LTO batteries. Fleets realize five-year total-cost-of-ownership parity once fuel savings and lower maintenance offset higher upfront prices.Fast-charging Electric Buses and Trucks: Transit authorities need battery systems that accept repeated high-power "opportunity charges" during short layovers. LTO cells replenish 80% capacity in roughly five minutes, allowing operators to shrink fleet size without sacrificing route frequency. U.S. Low-No Emission Bus grants earmark more than US$1.5 billion per year, with bid specifications that explicitly reference rapid-charge capability. Parallel subsidy programs in China reimburse up to CNY 80,000 (US$ 11,396) per new-energy bus, accelerating volume deployment in provincial capitals.Hybrid and BEV: Regenerative braking and high-C-rate acceleration favour the use of LTO batteries. Use in fast-charge EV stations is growing rapidly as ride-hailing fleets adopt swap-ready models.Stationary Storage: Utility-scale batteries now cycle multiple times per day for frequency regulation, peak shaving, and voltage support. Energy-storage-system integrators adopt LTO batteries for grid-frequency response where state-of-charge swings are shallow but frequent.Industrial Robotics: LTO batteries are used in continuous-duty forklifts that require partial charges during operator breaks.Aerospace and Defense: Unmanned aerial vehicles, missile auxiliaries, and soldier-worn power banks operating from -40 °C to +60 °C ambient.5-minute Battery-Swap Stations: Battery-as-a-service platforms require ultra-fast turnaround and high cycle life. CATL confirmed plans to install 1,000 swap stations in 2025 and 30,000-40,000 by 2030, each requiring packs that tolerate thousands of rapid exchanges without degradation.Sub-10 kWh Packs: Cordless construction tools, autonomous ground vehicles, and medical carts select LTO batteries to bypass daily pack swaps.12V starter replacement to Lead acid: GMG's G+AI battery technology would be a viable 12 V starter-battery replacement for lead-acid, offering lower weight, longer cycle life, good low-temperature performance and improved cold-cranking capability, together with excellent tolerance to storage at 0% state of charge. In suitable system designs, the chemistry's stable voltage behaviour can also reduce balancing requirements and simplify battery management, helping to lower overall system cost.Lifecycle Procurement Preference: Many government procurement frameworks now weigh lifecycle reliability higher than purchase price. For example, New Mexico awarded a US$ 400 million bus electrification contract that included stringent thermal-runaway resistance metrics. Europe's Clean Industrial Deal allocates capital for storage technologies that stabilize renewables, aligning well with LTO batteries' fast-response profile.Cylindrical Cells: accounted for 37.7% of LTO battery sales in 2024 as entrenched production lines and robust steel casings satisfied heavy-duty demand. Pouch designs address aerospace weight requirements and constrained dashboards in autonomous robots.Summary of Important Milestones for GMG's G+AI Battery Development: MonthImportant Milestones in the Development of the Graphene Aluminium Ion BatteryMay 2020GMG and UQ win Australian Research Council grant for Graphene battery developmenthttps://graphenemg.com/gmg-and-uq-wins-australian-research-council-grant-for-graphene-aluminium-ion-battery-development/ Apr 2021The University of Queensland and GMG kick off coin cell battery development projecthttps://graphenemg.com/gmg-the-university-of-queensland-research-uni-quest-kick-off-the-graphene-enhanced-aluminium-ion-battery-development-project/May 2021Graphene aluminium-ion battery performance data - Energy Density and Power Densityhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-performance-data/Jun 2021Graphene aluminium-ion battery performance data - Cycle Lifehttps://graphenemg.com/graphene-aluminium-ion-battery-performance-data/Jun 2021Significant potential battery customer market response to launch of batteryhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-progress-update/Jul 2021Investment decision for coin cell battery development centrehttps://graphenemg.com/gmg-battery-pilot-plant-investment/Oct 2021Construction starts for coin cell battery development centrehttps://graphenemg.com/construction-battery-pilotplant/Oct 2021Bosch Australia Manufacturing Solutions and GMG sign Letter of Intenthttps://graphenemg.com/gmg-and-bosch-sign-collaboration-arrangement-for-bosch-to-design-and-deliver-gmgs-graphene-aluminium-ion-battery-manufacturing-plant/Dec 2021Commencement coin cell battery development centrehttps://graphenemg.com/battery-pilot-plant/Dec 2021Initial coin cell batteries sent for customer feedbackhttps://graphenemg.com/graphene-aluminium-battery-customers-prototypes/Mar 2022Initial factory acceptance testing of semi-automated prototype battery cell assembly equipmenthttps://graphenemg.com/gmg-announces-initial-factory-acceptance-testing-of-semi-automated-prototype-battery-cell-assembly-equipment/Mar 2022Wood Engineering and GMG Sign a Letter of Intenthttps://graphenemg.com/gmg-and-wood-agree-collaboration-arrangement-for-wood-to-engineer-and-deliver-major-graphene-manufacturing-expansion-projects/May 2022Rio Tinto and GMG sign Letter of Intenthttps://graphenemg.com/gmg-riotinto-energysavings-battery/Jun 2022Commissioning of Pouch Cell Equipmenthttps://graphenemg.com/gmg-manufactures-first-pouch-cell/Jun 2022Bob Galyen, former chief technology officer of CATL, joins GMG technical advisory committee.https://graphenemg.com/gmg-technical-advisory-committee-leadership-team-additions-and-cfo-change/Aug 2022Investment decision for Phase 1 modular Graphene Production Planthttps://graphenemg.com/gmg-announces-phase-1-expansion-project-to-graphene-manufacturing-facility-for-energy-saving-products-and-batteries/Oct 2022Significant battery performance, cell and graphene production improvementshttps://graphenemg.com/gmgs-battery-update-significant-battery-performance-cell-and-graphene-production-improvements/Dec 2022Investment of $600k Battery Development Centrehttps://graphenemg.com/gmg-invests-au-600000-to-accelerate-battery-pouch-cell-customer-testing-development-in-2023/Feb 2023Australian Government Approval (AICIS) for production and sale of batteries.https://graphenemg.com/gmg-receives-regulatory-approval-to-enable-significant-commercial-sales/May 2023Battery Joint Development Agreement with Rio Tinto signedhttps://graphenemg.com/gmg-announces-battery-joint-development-agreement-with-rio-tinto/May 2023Battery Technology Readiness Level (BRTL) 2-3 reachedhttps://graphenemg.com/gmg-announces-battery-team-and-related-updates/May 2023Decision to switch to develop Pouch Cells (instead of Coin Cells)https://graphenemg.com/gmg-announces-battery-team-and-related-updates/Jul 2023Bob Galyen former chief technology officer of CATL joins GMG board of Directorshttps://graphenemg.com/graphene-manufacturing-group-appoints-former-chief-technology-officer-of-catl-limited-to-its-board-of-directors/Sep 2023Battery Pouch Cell Prototypes Multilayered Auto-Stacker Demonstrationhttps://graphenemg.com/gmg-graphene-aluminium-ion-battery-pouch-cell-prototypes-multilayered-auto-stacker-demonstration/Sep 2023Reaching 500 mAh capacity batteryhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Sep 2023Battery Technology Readiness Level (BRTL) 4 reachedhttps://graphenemg.com/gmg-achieves-500mah-graphene-aluminium-ion-battery-prototype-in-pouch-cell-format/Nov 2023Rio Tinto and GMG Partnership Video Launchedhttps://graphenemg.com/rio-tinto-gmg-battery-partnership-video-launch/Dec 2023Commissioning of modular Graphene Production Planthttps://graphenemg.com/graphene-manufacturing-group-commissions-modular-graphene-production-plant/Feb 20241000 mAh Capacity Reachedhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-1000-mah-capacity-reached-and-next-steps-toward-commercialisation/Mar 2024Graphene Manufacturing Group Secures AU$2 million Funding Grant from Queensland Government for Battery Pilot Planthttps://graphenemg.com/graphene-manufacturing-group-secures-au2-million-funding-grant-from-queensland-government-for-battery-pilot-plant/Aug 2024GMG's Graphene Aluminium-Ion Battery: Progress Update and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-progress-update-and-next-steps-toward-commercialisation/Mar 2025GMG's Graphene Aluminium-Ion Battery: Collaboration with World Leading USA Battery Innovation Centre and Next Steps Toward Commercialisationhttps://graphenemg.com/gmgs-graphene-aluminium-ion-battery-collaboration-with-world-leading-usa-battery-innovation-centre-and-next-steps-toward-commercialisation/ About BIC:BIC is a collaborative initiative designed to incorporate leadership from renowned universities, government agencies, and commercial enterprises. BIC is a public-private partnership and a not-for-profit organization focusing on the rapid development, testing and commercialization of safe, reliable and lightweight energy storage systems for defense and commercial customers. BIC is a unique organization that has been leading battery cell development for world leading battery companies for over 10 years and has carried out over 500 battery development projects.About GMGGMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041www.graphenemg.comNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding the lower cost to produce GMG G+AI batteries, expectations for GMG G+AI batteries in respect of charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system when development is completed, that the new hybrid electrolyte is chloride free and non-corrosive, that the cathode and anode technology employed enables very fast and stable charging, that GMG G+AI batteries provide significant cost and weight savings relative to copper, that G+AI batteries can achieve over 150 Wh/kg charged over 1 hour and 75 Wh/kg when charged over 6 minutes following further development of cathode, anode, electrolyte and component weights, that G+AI batteries will progress to BTRL 7 and 8, that the timeline for the battery cell roadmap is achievable, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and which offers weight, cost and complexity advantages to a metal case and increased energy density, expectations for the lack of a thermal management system or fireproofing precautions, expectations for material and manufacturing costs, expectations for sales of LTO batteries, expectations for G+AI batteries being substitutable for LTO batteries at lower cost, expectations that G+AI batteries are viable 12V starter battery replacements and the rationale therefor and the advantages of pouch design for aerospace weight requirements and constrained dashboards of autonomous robots.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions that GMG G+AI batteries can be produced at lower cost, as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries, the speed and stability of charging, that G+AI batteries will progress to BTRL 7 and 8, that a range of global companies in a variety of industries will be interested in working with GMG, that the battery pack design will be plastic and offer weight, cost and complexity advantages to a metal case and increased energy density, that the service agreement with the BIC will enable the Company to optimize its cell design and battery manufacturing equipment, and that the Company will be able to meet its overall timeline on the battery cell roadmap. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that GMG G+AI batteries cannot be produced at lower cost, or any of the assumptions as to charging time, energy density, life cycle, safety, thermal runway risk and the need for a thermal management system for G+AI batteries can not be achieved, G+AI batteries do not offer expected speed and stability of charging, that G+AI batteries will not progress to BTRL 7 and 8, that a range of global companies in a variety of industries will not be interested in working with GMG, that the battery pack design will not be plastic and not offer weight, cost and complexity advantages to a metal case and increased energy density, that the Company will not be able to optimize the electrochemical behaviour of the pouch cell through laboratory experimentation or at all, that the Company will not be able to meet its overall timeline on the battery cell roadmap, that the service agreement with the BIC will not enable the Company to optimize its cell design and battery manufacturing equipment and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 04, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.[1] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends Report[2] LFP: https://www.evlithium.com/catl-battery-cell/catl-150ah-lifepo4-battery-cell.htmlLNMC: https://keheng-battery.com/product/catl-nmc-3-7v-151ah-high-energy-density-battery-for-ev/LTO: https://www.global.toshiba/ww/products-solutions/battery/scib/product-next/product/cell/high-power.htmlLead Acid: https://www.altronics.com.au/p/s4530-12v-3.5ah-sealed-lead-acid-sla-battery/?srsltid=AfmBOoqZGMEIsX__YYOuRLC3nvYDFtNkf35qZYuYeoh3ACf4wrrOLISD[3] https://findingspress.org/article/21459-impact-of-charging-rates-on-electric-vehicle-batt[4] High-power type cells | SCiB™ Rechargeable battery | Toshiba[5] https://www.ritarpower.com/industry_information/The-Price-of-50-kWh-Lithium-Ion-Batteries-A-Comprehensive-Analysis_297.html#:~:text=Lithium%20Titanate%20(LTO)%20Batteries%3A,cost%20between%20%2440%2C000%20and%20%2460%2C000.[6] https://www.grepow.com/blog/battery-energy-density.html[7] Lithium Titanate Oxide Battery Market Size, Share & 2030 Growth Trends ReportTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/278044 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Dec 15, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for an independent listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement of the Company dated 22 April 2025 for details), has obtained the relevant licensing rights to the innovative oral JAK1 inhibitor povorcitinib (proposed English generic name: Povorcitinib Phosphate Tablets) (“povorcitinib” or the “Product”), which has been included in the list of Breakthrough Therapeutic Drugs by the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China (“NMPA”), with a proposed indication for adult patients with non-segmental vitiligo. This certification has the potential to accelerate the development and review process of the Product.Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo, moderate to severe hidradenitis suppurativa (HS) and prurigo nodularis in several countries outside China. A Phase 2 clinical trial for the treatment of asthma is also ongoing.In March 2023, Incyte announced that povorcitinib met the primary endpoint in a global multi-center Phase 2b clinical trial for non-segmental vitiligo. Results showed that after 24 weeks of treatment, compared with vehicle, total body repigmentation of patients treated with povorcitinib once daily was significantly improved. Furthermore, according to the extended Phase 2b trial, longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation with a favorable tolerability profile[1]. In August 2025, Dermavon received the drug clinical trial approval notice issued by NMPA to conduct clinical trials of povorcitinib for the treatment of non-segmental vitiligo and other indications. Dermavon has initiated the clinical development of the Product in China and may consider further initiating clinical development of povorcitinib in China for the treatment of skin-related diseases such as HS and prurigo nodularis in the future.Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[2]. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. If approved in China, povorcitinib could provide a differentiated treatment option for patients with non-segmental vitiligo.The Product's inclusion in the list of Breakthrough Therapeutic Drugs is expected to accelerate its development and review process in mainland China. If approved for marketing in China, the Product has the potential to synergize with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream) and the innovative drug currently under New Drug Application (NDA) review ruxolitinib phosphate cream, helping the product to quickly realize its clinical and commercial value and benefit more patients with skin diseases. Furthermore, if approved, the Product, together with topical ruxolitinib phosphate cream, will provide vitiligo patients with differentiated and comprehensive treatment options.The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement (the “License Agreement”) for povorcitinib on 31 March 2024 with Incyte, obtaining an exclusive license to research, develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights of povorcitinib in the Territory other than Mainland China to the Group (excluding Dermavon and its subsidiaries).About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. Results from a global multi-center Phase 2b clinical trial of the product for non-segmental vitiligo indication can be found on the Incyte official website: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-data-phase-2b-study-evaluating-povorcitinib2. Datas are from the China Insights Consultancy (CIC) reportCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com